Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixumistat in Newly Diagnosed Glioblastoma
NCT07884344Phase 1Recruiting
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of lixumistat in glioblastoma (GBM) (2 cohorts). Primary endpoint: Concentration of Lixumistat in Brain Tumor Tissue at 6 months. Planned start Dec 2026; status: recruiting.
02
Drugs
lixumistat
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07884344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07884344.